GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 60 Degrees Pharmaceuticals Inc (NAS:SXTP) » Definitions » Gross Margin %

60 Degrees Pharmaceuticals (60 Degrees Pharmaceuticals) Gross Margin % : -16.67% (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is 60 Degrees Pharmaceuticals Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. 60 Degrees Pharmaceuticals's Gross Profit for the three months ended in Dec. 2023 was $-0.02 Mil. 60 Degrees Pharmaceuticals's Revenue for the three months ended in Dec. 2023 was $0.13 Mil. Therefore, 60 Degrees Pharmaceuticals's Gross Margin % for the quarter that ended in Dec. 2023 was -16.67%.


The historical rank and industry rank for 60 Degrees Pharmaceuticals's Gross Margin % or its related term are showing as below:

SXTP' s Gross Margin % Range Over the Past 10 Years
Min: -93.72   Med: -30.15   Max: 67.77
Current: -87.01


During the past 4 years, the highest Gross Margin % of 60 Degrees Pharmaceuticals was 67.77%. The lowest was -93.72%. And the median was -30.15%.

SXTP's Gross Margin % is ranked worse than
95.56% of 743 companies
in the Biotechnology industry
Industry Median: 59.33 vs SXTP: -87.01

60 Degrees Pharmaceuticals had a gross margin of -16.67% for the quarter that ended in Dec. 2023 => No sustainable competitive advantage

The 5-Year average Growth Rate of Gross Margin for 60 Degrees Pharmaceuticals was 0.00% per year.


60 Degrees Pharmaceuticals Gross Margin % Historical Data

The historical data trend for 60 Degrees Pharmaceuticals's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

60 Degrees Pharmaceuticals Gross Margin % Chart

60 Degrees Pharmaceuticals Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Gross Margin %
67.77 26.72 -93.72 -87.01

60 Degrees Pharmaceuticals Quarterly Data
Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 540.54 -329.41 -206.67 -39.22 -16.67

Competitive Comparison of 60 Degrees Pharmaceuticals's Gross Margin %

For the Biotechnology subindustry, 60 Degrees Pharmaceuticals's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


60 Degrees Pharmaceuticals's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 60 Degrees Pharmaceuticals's Gross Margin % distribution charts can be found below:

* The bar in red indicates where 60 Degrees Pharmaceuticals's Gross Margin % falls into.



60 Degrees Pharmaceuticals Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

60 Degrees Pharmaceuticals's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=-0.2 / 0.254
=(Revenue - Cost of Goods Sold) / Revenue
=(0.254 - 0.475) / 0.254
=-87.01 %

60 Degrees Pharmaceuticals's Gross Margin for the quarter that ended in Dec. 2023 is calculated as


Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=-0 / 0.126
=(Revenue - Cost of Goods Sold) / Revenue
=(0.126 - 0.147) / 0.126
=-16.67 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


60 Degrees Pharmaceuticals  (NAS:SXTP) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

60 Degrees Pharmaceuticals had a gross margin of -16.67% for the quarter that ended in Dec. 2023 => No sustainable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


60 Degrees Pharmaceuticals Gross Margin % Related Terms

Thank you for viewing the detailed overview of 60 Degrees Pharmaceuticals's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


60 Degrees Pharmaceuticals (60 Degrees Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
1025 Connecticut Avenue NW, Suite 1000, Washington, D.C, WA, USA, 20036
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline products under development cover development programs for COVID-19, fungal, tick-borne, and other viral diseases through Arakoda and Celgosivir.
Executives
Charles W Allen director 1881 N. NASH STREET, UNIT 701, ARLINGTON VA 22209
Kentucky Technology Inc. 10 percent owner 824 BULL LEA RUN, SUITE 2100, LEXINGTON KY 40511
Cheryl Xu director 1025 CONNECTICUT AVENUE NW, SUITE 1000, WASHINGTON DC 20036
Paul Field director 1025 CONNECTICUT AVENUE NW, SUITE 1000, WASHINGTON DC 20036
Tyrone Miller officer: Chief Financial Officer 1025 CONNECTICUT AVENUE NW, SUITE 1000, WASHINGTON DC 20036
Geoffrey S Dow director, 10 percent owner, officer: CEO and President 1025 CONNECTICUT AVENUE NW, SUITE 1000, WASHINGTON DC 20036
Florida State University Research Foundation Inc. 10 percent owner 200 LEVY AVENUE, BUILDING A, SUITE 351, TALLAHASSEE FL 32310
Bryan Lee Smith officer: Chief Medical Officer 1025 CONNECTICUT AVENUE NW, SUITE 1000, WASHINGTON DC 20036
Stephen Toovey director 1025 CONNECTICUT AVENUE NW, SUITE 100, WASHINGTON DC 20036

60 Degrees Pharmaceuticals (60 Degrees Pharmaceuticals) Headlines

From GuruFocus